Alcohol metabolism changes on semaglutide — July 2024

LibrarianMeg said:

Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak.

That reframing is the part I needed.

Adding the clinical framing, because it changes how the question reads.

LondonLisa said:

...but the FDA says semaglutide...

Interesting point. I want to add some regulatory nuance: the FDA labeling reflects the specific clinical trial data submitted for approval. Real-world clinical practice often extends beyond the FDA label based on emerging evidence and clinical judgment.

Example: semaglutide was first approved for diabetes (Ozempic), then obesity (Wegovy). The molecule didn't change — our understanding of its applications expanded. Similarly, semaglutide may evolve as more data accumulates.

PharmD_Rodriguez said:

The dose-response is real but shallow at the top.

I read this differently from PharmD_Rodriguez, on substance rather than tone. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.

Adding the numbers, since they settle part of this. Keep the original post as written when you update it, and add the correction underneath. An edited-away mistake is invisible to the next person who makes it.

Worth separating that from alcohol, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

Moderator note: a couple of off-topic posts removed. Carry on.